CRISPR-Cas9 Gene Editing for Hereditary Retinal Dystrophies: 5-Year Outcomes

We report 5-year follow-up data from a phase II clinical trial of CRISPR-Cas9 gene editing therapy in patients with confirmed Leber congenital amaurosis type 10. Visual acuity improved in 78% of participants with no serious adverse events.